Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 8,333 | 15,451 | 2,502 | 0 | 0 |
| Gross Profit | 8,333 | 15,451 | 2,502 | N/A | N/A |
| Operating Expenses | 99,792 | 87,890 | 164,949 | 173,267 | 43,002 |
| Operating Income | -91,459 | -72,439 | -162,447 | -173,267 | -43,002 |
| Interest Expense | 102 | 4,998 | 3,798 | 1,428 | 28 |
| Other Income | 2,263 | -34,129 | 231 | 172 | -16,981 |
| Pre-tax Income | -89,298 | -111,566 | -166,014 | -174,523 | -60,011 |
| Net Income Continuous | -89,298 | -111,566 | -166,014 | -174,523 | -60,011 |
| Net Income | $-89,298 | $-111,566 | $-166,014 | $-174,523 | $-60,011 |
| EPS Basic Total Ops | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
| EPS Basic Continuous Ops | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
| EPS Diluted Total Ops | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
| EPS Diluted Continuous Ops | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
| EPS Diluted Before Non-Recurring Items | -0.35 | -0.96 | -3.78 | -4.64 | -3.40 |
| EBITDA(a) | $-90,214 | $-71,068 | $-161,275 | $-172,775 | $-42,993 |